Balance 2,3% glikoze, 1,75 mmol/l kalcijs, šķīdums peritoneālai dialīzei लातविया - लातवियाई - Zāļu valsts aģentūra

balance 2,3% glikoze, 1,75 mmol/l kalcijs, šķīdums peritoneālai dialīzei

fresenius medical care deutschland gmbh, germany - kalcija chloridum dihydricum, glikozes monohydricum, magnija chloridum hexahydricum, natrii chloridum, natrii lactatis risinājums - Šķīdums peritoneālai dialīzei

Balance 4,25% glikoze, 1,75 mmol/l kalcijs, šķīdums peritoneālai dialīzei लातविया - लातवियाई - Zāļu valsts aģentūra

balance 4,25% glikoze, 1,75 mmol/l kalcijs, šķīdums peritoneālai dialīzei

fresenius medical care deutschland gmbh, germany - kalcija chloridum dihydricum, glikozes monohydricum, magnija chloridum hexahydricum, natrii chloridum, natrii lactatis risinājums - Šķīdums peritoneālai dialīzei

Balance 4,25% glikoze, 1,25 mmol/l kalcijs, šķīdums peritoneālai dialīzei लातविया - लातवियाई - Zāļu valsts aģentūra

balance 4,25% glikoze, 1,25 mmol/l kalcijs, šķīdums peritoneālai dialīzei

fresenius medical care deutschland gmbh, germany - kalcija chloridum dihydricum, glikozes monohydricum, magnija chloridum hexahydricum, natrii chloridum, natrii lactatis risinājums - Šķīdums peritoneālai dialīzei

Balance 1,5% glikoze, 1,75 mmol/l kalcijs, šķīdums peritoneālai dialīzei लातविया - लातवियाई - Zāļu valsts aģentūra

balance 1,5% glikoze, 1,75 mmol/l kalcijs, šķīdums peritoneālai dialīzei

fresenius medical care deutschland gmbh, germany - kalcija chloridum dihydricum, glikozes monohydricum, magnija chloridum hexahydricum, natrii chloridum, natrii lactatis risinājums - Šķīdums peritoneālai dialīzei

Calrecia 100 mmol/l šķīdums infūzijām लातविया - लातवियाई - Zāļu valsts aģentūra

calrecia 100 mmol/l šķīdums infūzijām

fresenius medical care deutschland gmbh, germany - kalcija hlorīda dihidrāts - Šķīdums infūzijām - 100 mmol/l

Civaron 136 mmol/l šķīdums infūzijām लातविया - लातवियाई - Zāļu valsts aģentūra

civaron 136 mmol/l šķīdums infūzijām

fresenius medical care deutschland gmbh, germany - nātrija citrāts - Šķīdums infūzijām - 136 mmol/l

Alymsys यूरोपीय संघ - लातवियाई - EMA (European Medicines Agency)

alymsys

mabxience research sl - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiski līdzekļi - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

EndolucinBeta यूरोपीय संघ - लातवियाई - EMA (European Medicines Agency)

endolucinbeta

itm medical isotopes gmbh - lutetium (177lu) chloride - radionuklīdu attēlveidošana - terapeitiskie radiofarmaceitiskie preparāti - endolucinbeta ir radiofarmaceitisko prekursoru, un tas nav paredzēts tiešai izmantošanai pacientiem. to lieto tikai tādu pārvadātāja molekulu radioaktīvai iezīmēšanai, kas ir īpaši izstrādātas un atļautas radioaktīvai marķēšanai ar luteciu (177lu) hlorīdu.

TachoSil यूरोपीय संघ - लातवियाई - EMA (European Medicines Agency)

tachosil

corza medical gmbh - cilvēka fibrinogēns, cilvēka trombīns - hemostāze, ķirurģija - antihemorāģija - tachosil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. tachosil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.

Penthrox 99,9%, 3 ml inhalācijas tvaiki, šķidrums लातविया - लातवियाई - Zāļu valsts aģentūra

penthrox 99,9%, 3 ml inhalācijas tvaiki, šķidrums

medical developments ned b.v., netherlands - metoksiflurāns - inhalācijas tvaiki, šķidrums - 99,9%